Magic mushroom therapy takes on gambling addiction

NCT ID NCT07391332

Not yet recruiting Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study will test whether psilocybin (the active ingredient in magic mushrooms) combined with psychotherapy can help people with gambling disorder. Thirty adults will receive either a high dose (25-40 mg) or a very low dose (1 mg) of psilocybin during therapy sessions. The main goal is to see if the study is feasible and acceptable, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin (a psychedelic drug)
What this could lead to: If successful, this could point toward a new treatment option for gambling disorder using psychedelic-assisted therapy.
What could go wrong: This is a very small pilot study (30 people) testing feasibility, not effectiveness. It may not show clear benefits, and psilocybin can cause intense psychological experiences and temporary distress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GAMBLING DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pathological gambling

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GAMBLING DISORDER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Nantes University Hospital

Nantes, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.